GlassScriptPhysician profile
Lucienne Perceval
NPI 1184126427
$6,550.92
in general payments reported to CMS, 2019-2025
30 companies · $2,268 in 2025
The $2,268 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $369 · 2022: $1,050 · 2023: $1,370 · 2024: $1,494 · 2025: $2,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,010 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,009.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.17 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,069.31 | 2021-2025 | Livdelzi, Epclusa, Yeztugo |
| Viiv Healthcare Company | $722.33 | 2022-2025 | Rukobia, Apretude, Cabenuva |
| Novo Nordisk INC | $443.68 | 2024-2025 | Ozempic |
| Axsome Therapeutics, INC. | $360.40 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $353.46 | 2024-2025 | Airsupra, Breztri |
| Genzyme Corporation | $331.25 | 2022-2025 | |
| Biogen, INC. | $301.72 | 2022-2024 | |
| Grifols USA, LLC | $251.63 | 2022-2024 | Prolastin-C Liquid |
| Neurocrine Biosciences, INC. | $249.97 | 2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $242.43 | 2023 | Quviviq |
| Genentech USA, INC. | $215.53 | 2021-2023 | Evrysdi |
| Abbvie INC. | $177.99 | 2021-2022 | |
| Napo Pharmaceuticals INC | $154.65 | 2025 | Mytesi |
| Medtronic, INC. | $146.44 | 2025 | Symplicity G3 |
| Shield Therapeutics INC | $125.00 | 2023 | Accrufer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $120.72 | 2024 | |
| Paratek Pharmaceuticals, INC. | $116.43 | 2023 | Nuzyra |
| Eisai INC. | $111.59 | 2025 | |
| Astellas Pharma US INC | $111.57 | 2024 | Veozah |
| Abbott Laboratories | $108.26 | 2023 | Freestyle Libre 2 |
| Horizon Therapeutics Plc | $101.20 | 2022 | |
| Medicure Pharma INC. | $100.17 | 2024 | Zypitamag |
| Teva Pharmaceuticals USA, INC. | $100.00 | 2025 | |
| Abiomed | $95.55 | 2025 | |
| Glaxosmithkline, LLC. | $92.05 | 2024 | Arexvy |
| Grt US Holding, INC. | $88.55 | 2022 | |
| Janssen Pharmaceuticals, INC | $87.00 | 2022 | |
| Atricure, INC. | $79.01 | 2023 | |
| Theratechnologies INC. | $71.03 | 2021 | |
| Acella Pharmaceuticals, LLC | $22.00 | 2023 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucienne Perceval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.